A consensus paper published in 2025 provides pragmatic advice on the diagnosis and treatment of subsyndromal anxiety disorder (SSA). If it has been established that the patient has SSA, it is recommended that non-drug treatment measures be initiated first. If this does not lead to the desired success, drug therapy should be considered. Phytotherapeutic treatment with a standardized lavender oil extract has been shown to be effective and safe in studies of SSA.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- MASH
Pharmacotherapies as “Game Changers”—What Are the Upcoming Challenges?
- Obesity Treatment
Oral GLP-1 Therapies: ATTAIN-1 and OASIS-4—The Next Leap Forward
- Older patients with atopic dermatitis
Why the Use of Biologics Is Recommended
- Disorders of the Gut-Brain Interaction
Peppermint-Caraway Oil Supplement Proves Effective in Phase IV Trial
- Gepante for Migraines
Relief from pain, symptoms, and improved functional ability—both acute and preventive
- Why the Finerenon Boom Is Giving Hyperkalemia Treatment New Relevance
Potassium binders as enablers of RAASi optimization
- Asthma in Adults: Bronchodilation and Anti-Inflammatory Therapy
Remodeling can be counteracted through a proactive treatment strategy
- From symptom to diagnosis